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INTRODUCTION: Ventilator-associated pneumonia (VAP) is the first cause of
healthcare-associated infections in intensive care units (ICUs) and brain injury is
one of the main risk factors for early-onset VAP. Antibiotic prophylaxis has been
reported to decrease their occurrence in brain-injured patients, but a lack of
controlled randomised trials and the risk of induction of bacterial resistance
explain the low level of recommendations. The goal of this study is to determine
whether a single dose of ceftriaxone within the 12 hours postintubation after
severe brain injury can decrease the risk of early-onset VAP.
METHODS AND ANALYSIS: The PROPHY-VAP is a French multicentre,
randomised, double-blind, placebo-controlled, clinical trial. Adult brain-injured
patients (n=320) with a Glasgow Coma Scale ≤12, requiring mechanical ventilation
for more than 48 hours, are randomised to receive either a single dose of
ceftriaxone 2 g or a placebo within the 12 hours after tracheal intubation. The
primary endpoint is the proportion of patients developing VAP from the 2nd to the
7th day after mechanical ventilation. Secondary endpoints include the proportion
of patients developing late VAP (>7 days after tracheal intubation), the number of
ventilator-free days, VAP-free days and antibiotic-free days, length of stay in the
ICU, proportion of patients with ventilator-associated events and mortality during
their ICU stay.
ETHICS AND DISSEMINATION: The initial research project was approved by the
Institutional Review Board of OUEST III (France) on 20 October 2014 (registration
No 2014-001668-36) and carried out according to the principles of the Declaration
of Helsinki and the Clinical Trials Directive 2001/20/EC of the European Parliament
relating to the Good Clinical Practice guidelines. The results of this study will be
presented in national and international meetings and published in an international
peer-reviewed journal.
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